Jianfan Biotech announced that in the first half of 2026, the company's revenue was 1,032 million yuan, down 8.99% year on year; net profit attributable to shareholders of listed companies was 382 million yuan, down 1.99% year on year; net profit after deducting non-recurring profit and loss was 355 million yuan, down 4.71% year on year. Net cash flow from operating activities was $411 million, a year-on-year decrease of 23.61%. The company plans not to pay cash dividends, bonus shares, and not to use the Provident Fund to increase share capital.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.